STAT Plus: With new combination drug data, Exelixis takes another shot at prostate cancer treatment
ANNE WESTON/FRANCIS CRICK INSTITUTE/WELLCOME
A first attempt nearly shut down the company, but this time Exelixis appears to have delivered better, tumor-shrinking results, according to new data.
.png)
No hay comentarios:
Publicar un comentario